Search

Your search keyword '"Cao, Yanshuo"' showing total 47 results
Start Over Author "Cao, Yanshuo"
47 results on '"Cao, Yanshuo"'

11. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

Author

Xu, Yingying, Wang, Yakun, Gong, Jifang, Zhang, Xiaotian, Peng, Zhi, Sheng, Xinan, Mao, Chenyu, Fan, Qingxia, Bai, Yuxian, Ba, Yi, Jiang, Da, Yang, Fen, Qi, Changsong, Li, Jian, Wang, Xicheng, Zhou, Jun, Lu, Ming, Cao, Yanshuo, Yuan, Jiajia, Liu, Dan, Wang, Zhenghang, Fang, Jianmin, and Shen, Lin

Published
2021
Full Text
View/download PDF

12. Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer

Author

Gao, Mengting, primary, Wu, Xueying, additional, Jiao, Xi, additional, Hu, Ying, additional, Wang, Yanni, additional, Zhuo, Na, additional, Dong, Fengxiao, additional, Wang, Yujiao, additional, Wang, Fengyuan, additional, Cao, Yanshuo, additional, Liu, Chang, additional, Li, Jian, additional, Shen, Lin, additional, Zhang, Henghui, additional, and Lu, Zhihao, additional

Published
2024
Full Text
View/download PDF

13. Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein–producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.

Author

Wang, Yakun, primary, Wang, Chang, additional, Chen, Xiaofeng, additional, Peng, Zhi, additional, Gu, Yanhong, additional, Wang, Yizhuo, additional, Wang, Xicheng, additional, Li, Jian, additional, Gong, Jifang, additional, Qi, Changsong, additional, Yuan, Jiajia, additional, Lu, Zhihao, additional, Lu, Ming, additional, Shen, Lin, additional, Cao, Yanshuo, additional, and Zhang, Xiaotian, additional

Published
2024
Full Text
View/download PDF

17. Pyrotinib alone or in combination with docetaxel in refractory HER2 ‐positive gastric cancer: A dose‐escalation phase I study

Author

Liu, Dan, primary, Kou, Furong, additional, Gong, Jifang, additional, Wang, Zhiqiang, additional, Zhang, Xiaotian, additional, Li, Jian, additional, Li, Yan, additional, Li, Jie, additional, Zhou, Jun, additional, Lu, Ming, additional, Wang, Xicheng, additional, Lu, Zhihao, additional, Cao, Yanshuo, additional, Zou, Jianjun, additional, Zhu, Xiaoyu, additional, Xu, Ruihua, additional, and Shen, Lin, additional

Published
2023
Full Text
View/download PDF

18. Advanced prompting as a catalyst: Empowering large language models in the management of gastrointestinal cancers

Author

Yuan, Jiajia, primary, Bao, Peng, additional, Chen, Zifan, additional, Yuan, Mingze, additional, Zhao, Jie, additional, Pan, Jiahua, additional, Xie, Yi, additional, Cao, Yanshuo, additional, Wang, Yakun, additional, Wang, Zhenghang, additional, Lu, Zhihao, additional, Zhang, Xiaotian, additional, Li, Jian, additional, Ma, Lei, additional, Chen, Yang, additional, Zhang, Li, additional, Shen, Lin, additional, and Dong, Bin, additional

Published
2023
Full Text
View/download PDF

20. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Author

Zhou, Jun, primary, Sun, Yongkun, additional, Zhang, Wen, additional, Yuan, Jiajia, additional, Peng, Zhi, additional, Wang, Wei, additional, Gong, Jifang, additional, Yang, Lin, additional, Cao, Yanshuo, additional, Zhao, Hong, additional, Chen, Chao, additional, Wang, Weifeng, additional, Shen, Lin, additional, and Zhou, Aiping, additional

Published
2022
Full Text
View/download PDF

21. A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor

Author

Zhang, Qi, primary, Deng, Ting, additional, Yang, Fen, additional, Guo, Weijian, additional, Liu, Dan, additional, Yuan, Jiajia, additional, Qi, Changsong, additional, Cao, Yanshuo, additional, Yu, Qiuqiong, additional, Cai, Huiming, additional, Peng, Zhi, additional, Wang, Xicheng, additional, Zhou, Jun, additional, Lu, Ming, additional, Gong, Jifang, additional, Li, Jian, additional, Ba, Yi, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

23. A Phase Ib Study of KN026, a Bispecific Anti-HER2 Antibody, Combined with KN046, an Anti-CTLA-4/PD-L1 Antibody, in Patients with HER2-Positive Advanced Gastrointestinal Cancer

Author

Dong, Zhi, primary, Liu, Dan, additional, Gong, Jifang, additional, Zhang, Xiaotian, additional, Luo, Suxia, additional, Peng, Zhi, additional, Wang, Yakun, additional, Qi, Changsong, additional, Wang, Zhenghang, additional, Li, Jian, additional, Wang, Xicheng, additional, Lu, Ming, additional, Lu, Zhihao, additional, Zhou, Jun, additional, Cao, Yanshuo, additional, Yuan, Jiajia, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

26. Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma.

Author

Zhang, Jianwei, Cao, Yanshuo, Zhang, Panpan, Zhang, Xiaotian, Li, Jian, Zhou, Jun, Wang, Xicheng, Peng, Zhi, Sun, Yu, Li, Jie, Shen, Lin, and Lu, Ming

Subjects
*NEUROENDOCRINE tumors, *CARCINOEMBRYONIC antigen, *BIOMARKERS, *PROGNOSIS, *CANCER hospitals
Abstract

Objective: Gastroenteropancreatic neuroendocrine carcinoma (GEPNEC) is a major research focus, but the application of biomarkers to guide its prognostication and management is unsatisfying. Clinical values of conventional serum biomarkers, neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA199) warrant scrutiny. Methods: Patients diagnosed with GEPNEC with baseline NSE, CEA, and CA199 levels provided in Peking University Cancer Hospital were retrospectively studied. Relationships between biomarkers and prognosis were investigated by the χ2 test, Kaplan-Meier analysis, and univariate and multivariate Cox regression analyses. Results: A total of 640 GEPNEC patients were enrolled. NSE, CEA, and CA199 were elevated in 59.5%, 28.5%, and 21.3% of the population, respectively. Higher NSE had worse median overall survival (OS) (17.0 months vs. not reached, hazard ratio = 2.77 [2.06, 3.73], p < 0.001), and so did patients with higher CEA and CA199. Multivariable analysis confirmed that NSE and CA199 correlated with OS independently. Baseline NSE level and NSE remission predicted OS and the response of patients with first-line etoposide plus cisplatin (EP) treatment. Furthermore, we combined NSE/CEA/CA199 to segregate GEPNEC into novel subgroups, namely, adenocarcinoma-like NEC (ALN), neuroendocrine-like NEC (NLN), and triple-normal NEC (TNN). The groups shared distinctive clinicopathologic features and prognosis (21.0 months vs. 17.1 months vs. not reached, p < 0.001). The EP regimen remained the priority treatment option in NLN/TNN, while ALN was predisposed to "adenocarcinoma-like chemotherapy." Conclusions: Elevation of NSE, CEA, or CA199 was common and independently indicates poor prognosis in GEPNEC patients. Serum biomarker-based subtypes suggest meaningful clinical implications and appropriate therapeutic approaches, illuminating promising ways to characterize the prognosis of GEPNEC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial

Author

Lu, Zhihao, primary, Fang, Yu, additional, Liu, Chang, additional, Zhang, Xiaotian, additional, Xin, Xiaowei, additional, He, Yi, additional, Cao, Yanshuo, additional, Jiao, Xi, additional, Sun, Tianqi, additional, Pang, Ying, additional, Wang, Yanli, additional, Zhou, Jun, additional, Qi, Changsong, additional, Gong, Jifang, additional, Wang, Xicheng, additional, Li, Jian, additional, Tang, Lili, additional, and Shen, Lin, additional

Published
2021
Full Text
View/download PDF

32. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines

Author

Chen, Christine I., primary, Cao, Yanshuo, additional, Trudel, Suzanne, additional, Reece, Donna E., additional, Kukreti, Vishal, additional, Tiedemann, Rodger, additional, Prica, Anca, additional, Paul, Harminder, additional, Le, Lisa W., additional, Levina, Olga, additional, Kakar, Sumeet, additional, Lau, Anthea, additional, Chen, Hongzhuan, additional, and Chen, Eric, additional

Published
2020
Full Text
View/download PDF

33. Early Interdisciplinary Palliative Care in Patients with Previously Untreated Metastatic Oesophagogastric Cancer: A Phase 3 Randomised Controlled Trial

Author

Lu, Zhihao, primary, Fang, Yu, additional, Liu, Chang, additional, Zhang, Xiaotian, additional, Xin, Xiaowei, additional, He, Yi, additional, Cao, Yanshuo, additional, Jiao, Xi, additional, Sun, Tianqi, additional, Pang, Ying, additional, Wang, Yanli, additional, Zhou, Jun, additional, Qi, Changsong, additional, Gong, Jifang, additional, Wang, Xicheng, additional, Li, Jian, additional, Tang, Lili, additional, and Shen, Lin, additional

Published
2020
Full Text
View/download PDF

36. An updated retrospective review of the safety and efficacy of sorafenib for recurrent hepatocellular carcinoma post-liver transplantation.

Author

Feng, Sophie, primary, Fallah-Rad, Nazanin, additional, Cao, Yanshuo, additional, Knox, Jennifer J., additional, Jang, Raymond Woo-Jun, additional, Dhani, Neesha C., additional, Sapisochin, Gonzalo, additional, Grant, David, additional, Greig, Paul D, additional, Lilly, Leslie, additional, Gorgen, Andre, additional, and Chen, Eric Xueyu, additional

Published
2019
Full Text
View/download PDF

37. Helicobacter pyloriand immunotherapy for gastrointestinal cancer

Author

Jia, Keren, Chen, Yang, Xie, Yi, Wang, Xicheng, Hu, Yajie, Sun, Yu, Cao, Yanshuo, Zhang, Liyan, Wang, Yakun, Wang, Zhenghang, Lu, Zhihao, Li, Jian, Zhang, Xiaotian, and Shen, Lin

Abstract

Helicobacter pyloriinfection is associated with the risk of gastrointestinal (GI) cancers; however, its impact on immunotherapy for GI cancers remains uncertain. In this study, we included 10,122 patients who underwent 13C-urea breath tests. Among 636 patients with Epstein-Barr virus–negative microsatellite-stable gastric cancer (GC) who were treated with anti-PD-1/PD-L1 therapy, H. pylori–positive patients exhibited significantly longer immune-related progression-free survival (irPFS) compared with H. pylori–negative patients (6.97 months versus 5.03 months, p < 0.001, hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.62–0.95, p = 0.015). Moreover, the H. pylori–positive group demonstrated a trend of 4 months longer median immune-related overall survival (irOS) than the H. pylori–negative group. H. pylori–positive GC displayed higher densities of PD-L1+cells and nonexhausted CD8+T cells, indicative of a “hot” tumor microenvironment. Transcriptomic analysis revealed that H. pylori–positive GC shared molecular characteristics similar to those of immunotherapy-sensitive GC. However, H. pylori–positive patients with DNA mismatch repair–deficient (dMMR)/microsatellite instability–high (MSI-H) colorectal adenocarcinoma and esophageal squamous cell carcinoma (ESCC) had shorter irPFS compared with H. pylori–negative patients (16.13 months versus not reached, p = 0.042, HR 2.26, 95% CI 1.13–4.50, p = 0.021 and 5.57 months versus 6.97 months, p = 0.029, HR 1.59, 95% CI 1.14–2.23, p = 0.006, respectively). The difference in irOS between H. pylori–positive and –negative patients had the same trend as that between dMMR/MSI-H colorectal adenocarcinoma and ESCC patients. We also identified a trend of shorter irPFS and irOS in H. pylori–positive liver cancer and pancreatic cancer patients. In summary, our findings supported that H. pyloriinfection is a beneficial factor for GC immunotherapy by shaping hot tumor microenvironments. However, in dMMR/MSI-H colorectal adenocarcinoma and ESCC patients, H. pyloriadversely affects the efficacy of immunotherapy.

Published
2024
Full Text
View/download PDF

38. Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients

Author

Cao, Yanshuo, primary, Chang, Qing, additional, Cabanero, Michael, additional, Zhang, Wenjiang, additional, Hafezi-Bakhtiari, Sara, additional, Hedley, David, additional, Darling, Gail, additional, Quereshy, Fayez, additional, Jang, Raymond, additional, Elimova, Elena, additional, Knox, Jennifer, additional, Ornatsky, Olga, additional, Serra, Stefano, additional, and Chen, Eric, additional

Published
2018
Full Text
View/download PDF

40. Tumor platinum concentrations and pathological responses following preoperative cisplatin-containing chemotherapy in gastric or gastroesophageal junction cancer patients.

Author

Cao, Yanshuo, primary, Chang, Qing, additional, Cabanero, Michael, additional, Zhang, Wenjiang, additional, Hafezi-Bakhtiari, Sara, additional, Hedley, David W., additional, Darling, Gail Elizabeth, additional, Quereshy, Fayez A., additional, Jang, Raymond Woo-Jun, additional, Elimova, Elena, additional, Knox, Jennifer J., additional, Ornatsky, Olga, additional, Serra, Stefano, additional, and Chen, Eric Xueyu, additional

Published
2018
Full Text
View/download PDF

46. Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer.

Author

Li Y, Zhang X, Gong J, Zhang Q, Gao J, Cao Y, Wang DD, Lin PP, and Shen L

Abstract

Objective: Previous work indicated that aneuploidy of chromosome 8 in circulating tumor cells (CTCs) correlated with therapeutic efficacy for advanced gastric cancer (AGC) patients. In this follow-up study performed on the same population of AGC patients, we investigated whether and how aneuploidy of chromosome 8 in CTCs correlates with patients' clinical prognosis., Methods: The prospective study was performed on 31 patients with newly diagnosed AGC. Previously established integrated subtraction enrichment (SE) and immunostaining-fluorescence in situ hybridization (iFISH) platform was applied to identify, enumerate and characterize CTCs. Quantification of CTCs and analysis of their aneuploidy of chromosome 8 were performed on patients before and after therapy., Results: CTCs were measured in 93.5% of AGC patients, and two CTC subtypes with diverse threshold values were identified, multiploid CTCs with the threshold of ≥2 per 7.5 mL and multiploid plus triploid CTCs with the threshold of ≥4, which were found to significantly correlate with poor progression-free survival (PFS) and overall survival (OS). In particular, patients with ≥10% increased multiploid CTCs after an initial 6 weeks of therapy had poor PFS and OS, whereas improved PFS and OS were observed on those who had ≥10% decreased multiploid CTCs. After adjusting for clinically significant factors, ≥10% increased post-therapy multiploid CTCs was the only independent predictor of PFS and OS., Conclusions: Aneuploidy of CTCs correlates with prognosis of AGC patients. Quantitative comparison monitoring multiploid CTCs before and after therapy may help predict improved or inferior prognosis and chemoresistance.

Published
2016
Full Text
View/download PDF

47. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].

Author

Zhang X, Wu Y, Gong J, Lu Z, Zhou J, Wang X, Lu M, Li J, Cao Y, Li Y, Li J, and Shen L

Subjects
Adenocarcinoma metabolism, Adenocarcinoma secondary, Adenocarcinoma surgery, Adult, Aged, Anorexia chemically induced, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Camptothecin administration & dosage, Camptothecin adverse effects, Camptothecin analogs & derivatives, Cisplatin administration & dosage, Cisplatin adverse effects, Disease Progression, Disease-Free Survival, Drug Resistance, Neoplasm, Fatigue chemically induced, Female, Follow-Up Studies, Humans, Irinotecan, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Male, Middle Aged, Neutropenia chemically induced, Paclitaxel administration & dosage, Paclitaxel adverse effects, Pyrimidines administration & dosage, Pyrimidines adverse effects, Receptor, ErbB-2 metabolism, Remission Induction, Retrospective Studies, Stomach Neoplasms metabolism, Stomach Neoplasms secondary, Stomach Neoplasms surgery, Survival Rate, Trastuzumab, Adenocarcinoma drug therapy, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Esophagogastric Junction, Stomach Neoplasms drug therapy
Abstract

Objective: To evaluate the efficacy and safety of trastuzumab combined with chemotherapy in the treatment for HER-2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma., Methods: Twenty consecutive cases of chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma treated in Peking University Cancer Hospital between 2009 June and 2013 August were included in this study. The patients with adenocarcinoma were previously confirmed and were eligible if their tumor showed overexpression of HER-2+++ by immunohistochemistry or HER-2 gene amplification-positive by FISH, and if they failed to at least one previous chemotherapy. Response and toxicities were evaluated with RECIST 1.0 and CTC AE 3.0 criteria., Results: The twenty patients received trastuzumab plus second- or later-line chemotherapy, consisting of nine platinum with fluoropyrimidines, five paclitaxel with fluoropyrimidines, three fluoropyrimidines monotherapy, two irinotecan monotherapy, and one docetaxel monotherapy. In these 20 cases, 3 PR (15.0%) and 10 SD (50.0%) were achieved, with a disease control rate of 65.0%. The median PFS was 6.1 months (95%CI 3.0-9.2) and median OS was 11.1 months (95%CI 8.4-13.7). The median cycle number of Trastuzumab administration was 6.5. The patients treated with Trastuzumab ≥ 6 times had a median OS of 13.8 months, significantly longer than that of 9.5 months in the patients treated <6 times (P < 0.001). The patients treated with Trastuzumab ≥ 6 times had a median PFS of 7.8 months, significantly longer than that of 3.7 months in patients treated <6 times (P = 0.029). Among the 20 cases, loss of appetite (13 cases of grade 1-2), neutropenia (12 cases of grade 1-2 and 3 cases of grade 3-4) and fatigue (9 cases of grade 1-2 and 3 cases of grade 3-4) were the most frequent adverse events. No cardiac events including asymptomatic decreases in LVEF ≥ 10% and no treatment-related death were recorded., Conclusions: Combination of trastuzumab with chemotherapy is effective and safe in patients with HER2-positive advanced chemo-refractory gastric or gastro-esophageal junction adenocarninoma. However, prospective studies are warranted to further confirm its efficacy and safety.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results